Austco Healthcare Targets 52-58% NPAT Jump on US Rollout

Austco Healthcare (ASX: AHC) has released a detailed FY26 forecast that pins the year's growth on a single large US deployment and a string of new contracts in Australia, New Zealand, and Canada. The guidance gives investors specific revenue and profit targets. The assumptions behind them – especially the timing of the US rollout – deserve closer scrutiny.

The company projects FY26 revenue between A$90 million and A$95 million, up 11% to 17% from FY25. Net profit after tax (NPAT) is forecast at A$9.0 million to A$9.4 million, a 52% to 58% increase. Earnings before interest, taxes, depreciation, and amortization (EBITDA) is guided at A$14 million to A$14.6 million, implying an EBITDA margin of about 15.5%, a slight dip from the 16.0% reported in FY25.

The headline numbers look strong. The composition matters. The NPAT forecast includes a one-off benefit of roughly A$1.0 million from a reduction in contingent consideration related to the G&S acquisition. Strip that out, and the underlying NPAT growth narrows to roughly 40% to 48% – still healthy, softer than the headline 52-58% range.

The gross margin is expected to improve to about 52.8% from 52.0% in FY25, supported by a higher mix of recurring software and maintenance revenue. That margin expansion is the structural positive in the outlook.

The US Pulse Mobile Rollout as the Primary Catalyst

The single biggest driver for FY26 is the planned deployment of Austco's Pulse Mobile system across approximately 180 hospitals for its largest US customer. The contract is set to roll out over calendar 2026, which means the revenue recognition will be spread across the year. Execution risk is concentrated.

Delivery and Revenue Recognition Mechanics

A rollout of this scale across 180 hospital sites involves site surveys, installation, integration with existing hospital IT systems, and user training. Delays in any of these steps – especially if hospital construction timetables slip or IT approvals stall – could push revenue from the first half into the second half, or from FY26 into FY27.

Austco has flagged exactly this risk. Management cited slower construction programs in some regions that have already deferred some installations. The company frames these as timing shifts, not lost business. For a guided revenue range with a relatively tight A$5 million spread, even a few hospital site delays could push the final figure toward the lower end.

Larger Customer Concentration Risk

The US contract concentrates revenue exposure to a single customer procurement cycle. If that customer's capital expenditure budget changes, or if the hospital chain faces its own operational disruptions, Austco has limited diversification to absorb the hit within FY26.

New Contracts Provide Pipeline Backstop

Austco has also secured several smaller meaningful new contracts that provide some buffer against US rollout delays.

Contract Detail and Geographic Spread

NZ residential portfolio RFP: valued at approximately NZ$1.1 million
Warrnambool Hospital Expansion (Australia): worth about A$1.1 million
North York General Hospital long-term care (Canada): valued at roughly A$0.9 million

These contracts span three geographies and cover different facility types – residential care, hospital expansion, and long-term care. The geographic spread reduces dependence on any single regional construction cycle.

Recurring Revenue Visibility

Austco exited the first half of FY26 with A$47.2 million in unfilled contracted revenue (UCR). This backlog provides multi-period revenue visibility and supports the recurring software and maintenance revenue growth that is driving the gross margin improvement.

First Half Results Set the Benchmark

The FY26 guidance follows a strong first half of FY26 (1H26) that already delivered a record performance.

1H26 Results in Context

Revenue: A$48.2 million, up 30.7% year-over-year

EBITDA: A$8.3 million, up 60.1%

EBITDA margin: 17.1%, up from 14.0% in 1H25

The 1H26 margin of 17.1% is well above the full-year guidance of 15.5%. That implies the second half margin will contract relative to 1H26, likely due to the investment spend that management mentioned. A 17.1% first-half margin that drops to 14% or lower in the second half would still produce the guided full-year average.

Operational Headwinds: Supply Chain and Logistics

Austco is navigating several operational pressures that could affect margin and delivery timing.

Semiconductor Lead Times

Strong AI-driven demand for advanced semiconductors is extending component lead times. Austco's hardware products use these components. If lead times stretch further, the US hospital rollout could face procurement delays, which would push revenue out of FY26.

Freight and Logistics Costs

Higher logistics costs and longer freight transit times are partially attributed to geopolitical disruptions. These costs tend to hit hardware-based revenue more than software or maintenance streams, which dilutes the gross margin benefit from the recurring revenue mix.

Construction Program Slips

As flagged, slower construction at customer sites has caused some installation deferrals. Austco is treating these as revenue timing shifts, not cancellations. The risk is cumulative: if multiple headwinds converge, the FY26 revenue could come in at the low end of the range.

Bull Case vs. Risk Case for FY26

What Would Confirm the Setup

The US Pulse Mobile rollout hits the first 40-50 hospitals by mid-2026, confirming delivery cadence

Gross margin sustains above 52.5%, supported by recurring revenue growth

The UCR backlog grows above A$50 million by June 2026, signaling pipeline expansion

What Would Weaken the Thesis

Any sign that UCR additions are slowing or that UCR conversion is extending beyond 12 months

Component lead times push first US hospital installations into Q3 or Q4 calendar 2026

EBITDA margin falls below 14.5% for a sustained period, indicating cost creep beyond the investment plan

The FY26 guidance gives Austco a clear target to hit and a set of milestones to track. The US deployment is the swing factor. For more on the broader small-cap market context, readers can explore our stock market analysis or review the Austco Healthcare profile for historical performance data.